1. Xenon preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo† 
N.C. Weber, J. Stursberg, N.M. Wirthle, O. Toma, W. Schlack, B. Preckel 
British Journal of Anaesthesia 
Volume 97, Issue 3, Pages (September 2006)
DOI: /bja/ael153
Copyright © 2006 British Journal of Anaesthesia Terms and Conditions

2. Fig 1
(a and b) Experimental protocol: Xe, xenon; PC, preconditioning; SP , inhibitor of the JNK 1/2/3; PD 98059, inhibitor of the ERK 1/2 kinase pathway.
British Journal of Anaesthesia  , DOI: ( /bja/ael153)
Copyright © 2006 British Journal of Anaesthesia Terms and Conditions

3. Fig 2
Infarct size measurement. Histogram shows the infarct size (per cent of area at risk, AAR) of control (con), xenon preconditioning (Xe-PC), PD (PD) alone, SP (SP) alone, Xe-PC+PD and Xe-PC+SP group. Data show means (sd). *P<0.05, **P<0.01 vs control group, $$P<0.01 vs Xe-PC.
British Journal of Anaesthesia  , DOI: ( /bja/ael153)
Copyright © 2006 British Journal of Anaesthesia Terms and Conditions

4. Fig 3
JNK 1/2/3 time course of phosphorylation. One representative western blot experiment of cytosolic fraction of control and xenon (Xe-PC time 1-4) (n=4 each) is shown. (a) Upper panel shows phosphorylated form of JNK 1/2/3, lower panel total JNK 1/2/3. (b) The histogram presents densitometric evaluation as AVI: (left) quals;pJNK (phospho JNK 1, 46 kDa); (right) JNK 2 and 3 (phospho JNK 2 and 3, 54 kDa). Controls were set as 1. Data show ratio of phosphorylated vs total JNK 1/2/3. Data are means (sd). Actin served as internal standard.
British Journal of Anaesthesia  , DOI: ( /bja/ael153)
Copyright © 2006 British Journal of Anaesthesia Terms and Conditions

5. Fig 4
(a) Phosphorylation and translocation of ERK 1/2 MAPK in cytosolic and particulate fraction. Cytosolic (upper panel) and particulate (lower panel) fraction of control and xenon (Xe-PC time 1-4) groups (n=4 each) immunoblotted using antibodies against phospho ERK 1/2 (upper blot) and total ERK 1/2 (lower blot). The histograms (upper ERK 1, lower ERK 2) present densitometric evaluation as AVI. Data show ratio of phospho ERK 1/2 in the particulate to phospho ERK 1/2 in the cytosolic fraction. Data are means (SD). *P<0.05, **P<0.01 vs control group. (b) ERK 1/2 MAPK activity assay in cytosolic and particulate fraction. One representative western blot experiment after immunoprecipitation of active ERK 1/2 MAPK and incubation with ATP of cytosolic and particulate fraction of control and xenon (Xe-PC time 1–4) groups (n=4 each) is shown. Upper panel shows phosphorylated form of Elk-1, lower panel total Elk-1.
British Journal of Anaesthesia  , DOI: ( /bja/ael153)
Copyright © 2006 British Journal of Anaesthesia Terms and Conditions